COMPANY Data
Movers and SHAKERS

Ticker | CRDF (Nasdaq) |
Current Price | $8.25 ↓ -0.03 |
Market Cap | 305.68M |
Price Target | $23.00 |
Volume | 303.25k |
52wk Range | $0.83 - $25.50 |
ADVANCED MARKET DATA |

Advanced Market Data
Cardiff Oncology Inc. (CRDF)





Overview
Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit https://www.cardiffoncology.com.
- Industry/Sector Report
- Corporate Presentation
- Corporate Events
- Press Releases/News Feed
- ChannelCAST Videos [2]
- Senior Equity Research Analyst
- Corporate Filings
Cardiff Oncology Inc. Corporate Filings
Cardiff Oncology Inc. Corporate Events
Cardiff Oncology Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available
Noble Capital Markets Analyst
Holds FINRA licenses 7, 79, 86, 87.
Full Bio & Coverage List